Having shown that NT1-tau can readily be detected in plasma from patients with CJD, and at levels elevated versus AD and HC (Figure 3), we next investigated whether NT1-tau levels change with the progression of CJD. This evidence concerns the gene MAPT and Creutzfeldt Jacob disease.